Half Of US FDA’s Breakthrough Therapy Designations Have Resulted In Approval

Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.

Breakthrough-designated products stand a good chance of getting US FDA approval. • Source: photo illustration - shutterstock images

More from Review Pathways

More from Pathways & Standards